Qureator invites you to unlock your drug’s potential at AACR 2025, booth #5016! Explore how our cutting-edge vascularized 3D tumor models enable advanced evaluation of immuno-oncology drug efficacy and mechanism of action (MOA). Learn how reshaping the Tumor Immune Microenvironment (vTIME) drives enhanced T cell activation and synergistic responses with pembrolizumab, powered by real patient-derived organoids (PDOs). Additionally, discover how our AI-driven metastatic gastric cancer MPS model has identified novel monotherapy and combination targets, paving new pathways for one of oncology’s most challenging diseases. Visit us to experience the future of precision drug development.
https://www.linkedin.com/posts/qureatorinc_aacr25-drugdiscovery-preclinicalmodels-activity-7322329126982291456-8Mvs?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAluEwBTFpLwu-91jAPnRgOUU7_S8cHYhU